Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials
Addiction · 2023
DOI: 10.1111/add.16147 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Addiction, 2023. Verfasst von Daniela K van Santen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Drug Users, Hepatitis C, HIV Infections. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Medical Research Council, NIDA NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Background and Aims Although the Netherlands, Canada and Australia were early adopters of harm reduction for people who inject drugs (PWID), their respective HIV and hepatitis C (HCV) epidemics differ. We measured the pooled effect of needle and syringe program (NSP) and opioid agonist therapy (OAT) participation on HIV and HCV incidence in these settings.
Design
For each cohort, we emulated the design and statistical analysis of a target trial using observational data. Setting and Participants We included PWID at risk of HIV or HCV infection from the Amsterdam Cohort Studies (1985–2013), Vancouver Injection Drug Users Study (1997–2009) and Melbourne Injecting Drug User Cohort Study (SuperMIX) (2010–2021).
Measurements
Separately for each infection and cohort (only HCV in SuperMIX), marginal structural models were used to compare the effect of comprehensive (on OAT and 100% NSP coverage or on OAT only if no recent injection drug use) versus no/partial NSP/OAT (no OAT and/or
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, Amsterdam, The Netherlands.
- Department of Disease Elimination, Burnet Institute, Melbourne, Australia.
- School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.
- Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
- British Columbia Centre on Substance Use, Vancouver, Canada.
- Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.
ORCID-Profile: Daniela K van Santen, Kanna Hayashi, Lisa Maher, Matthew Hickman
Förderung
- Medical Research Council
- NIDA NIH HHS
- NIAID NIH HHS
Zitieren
APA
van Santen, D. K., Lodi, S., Dietze, P., van den Boom, W., Hayashi, K., Dong, H., Cui, Z., Maher, L., Hickman, M., Boyd, A., & Prins, M. (2023). Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. Addiction. https://doi.org/10.1111/add.16147
Vancouver
van Santen DK, Lodi S, Dietze P, van den Boom W, Hayashi K, Dong H, et al. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. Addiction. 2023. doi:10.1111/add.16147
BibTeX
@article{vanSanten2023,
author = {van Santen, Daniela K and Lodi, Sara and Dietze, Paul and van den Boom, Wijnand and Hayashi, Kanna and Dong, Huiru and Cui, Zishan and Maher, Lisa and Hickman, Matthew and Boyd, Anders and Prins, Maria},
title = {Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials},
journal = {Addiction},
year = {2023},
doi = {10.1111/add.16147}
}
EUVIMED